SCHEMBL4139729

SCHEMBL4139729

Nc1nccc2[nH]c(Sc3ccc4c(c3)CCO4)nc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
DYRK1A Q13627 2/20 0.40
CHRM5 P08912 1/20 0.35
CHRM1 P11229 1/20 0.35
PTPN11 Q06124 1/20 0.35
PRKCI P41743 1/20 0.34
PIK3CD O00329 1/20 0.34
ABL1 P00519 1/20 0.34
EGFR P00533 1/20 0.34
HCK P08631 1/20 0.34
SRC P12931 1/20 0.34
KDR P35968 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
MTOR P42345 1/20 0.34
PIK3CG P48736 1/20 0.34
EPHB4 P54760 1/20 0.34
PRKDC P78527 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3122647 0.83 PIK3CD (0.41) MAPTRAB9ASMN1; SMN2DYRK1ACHRM5
SCHEMBL1745214 0.75 HSP90AA1 (0.52) HSP90AA1
SCHEMBL4136081 0.75 DYRK1A (0.45) DYRK1APIK3CDABL1EGFRHCK
SCHEMBL1669303 0.74 ATG7 (0.38) MAPTRAB9ASMN1; SMN2DYRK1APIK3CD
SCHEMBL4142204 0.73 HSP90AA1 (0.50) HSP90AA1
SCHEMBL20427923 0.72 HSP90AA1 (0.56) HSP90AA1
SCHEMBL16487336 0.71 HSP90B1 (0.43) HSP90AA1
SCHEMBL4134203 0.70 HSP90AA1 (0.66) HSP90AA1
SCHEMBL4896589 0.70 HSP90AA1 (0.52) HSP90AA1
SCHEMBL1744449 0.70 HSP90AA1 (0.57) HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192687-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2023-06-22 US disclosed
US-11560377-B2 Fused amino pyridine as HSP90 inhibitors Guris, Inc. (US) 2023-01-24 US disclosed
US-20210292317-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2021-09-23 US disclosed
US-10844056-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2020-11-24 US disclosed
US-20200062754-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2020-02-27 US disclosed
US-10428068-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2019-10-01 US disclosed
US-20190010152-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2019-01-10 US disclosed
US-10035797-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2018-07-31 US disclosed
US-20170267674-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2017-09-21 US disclosed
US-9630965-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2017-04-25 US disclosed
US-20160058742-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2016-03-03 US disclosed
US-9040556-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2015-05-26 US disclosed
US-20140221343-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS, INC. (US) 2014-08-07 US disclosed
US-8586605-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2013-11-19 US disclosed
EP-2069324-B1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2013-07-31 EP disclosed
US-8324240-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2012-12-04 US disclosed
US-20120237508-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS, INC. 2012-09-20 US disclosed
EP-2069324-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS Curis, Inc. (US) 2009-06-17 EP disclosed
WO-2008115719-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS, INC. (US) 2008-09-25 WO disclosed
US-20080234314-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS, INC. 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190010152-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P MAPT 215/4885RAB9A 1177/4885SMN1; SMN2 2620/4885
US-10428068-B2 Fused amino pyridine as HSP90 inhibitors HSP90B1, HSP90AB1, HSP90AB2P MAPT 215/4885RAB9A 1177/4885SMN1; SMN2 2620/4885
US-20170267674-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P MAPT 215/4885RAB9A 1177/4885SMN1; SMN2 2620/4885
US-20160058742-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P MAPT 215/4885RAB9A 1177/4885SMN1; SMN2 2620/4885
US-20120237508-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P MAPT 215/4885RAB9A 1177/4885SMN1; SMN2 2620/4885
US-20230192687-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P MAPT 215/4885RAB9A 1177/4885SMN1; SMN2 2620/4885
US-20080234314-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P MAPT 215/4885RAB9A 1177/4885SMN1; SMN2 2620/4885
US-20210292317-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P MAPT 215/4885RAB9A 1177/4885SMN1; SMN2 2620/4885
US-20200062754-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P MAPT 215/4885RAB9A 1177/4885SMN1; SMN2 2620/4885
US-20140221343-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P MAPT 215/4885RAB9A 1177/4885SMN1; SMN2 2620/4885
US-11560377-B2 Fused amino pyridine as HSP90 inhibitors HSP90B1, HSP90AB1, HSP90AB2P MAPT 215/4885RAB9A 1177/4885SMN1; SMN2 2620/4885
US-10844056-B2 Fused amino pyridine as HSP90 inhibitors HSP90B1, HSP90AB1, HSP90AB2P MAPT 215/4885RAB9A 1177/4885SMN1; SMN2 2620/4885
US-10035797-B2 Fused amino pyridine as HSP90 inhibitors HSP90B1, HSP90AB1, HSP90AB2P MAPT 215/4885RAB9A 1177/4885SMN1; SMN2 2620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.